Valuation: Celltrion, Inc.

Market Cap 42,52800Cr 3.11TCr 2.69TCr 2.55TCr 2.31TCr 4.33TCr 2,98200Cr 4.36TCr 30TCr 12TCr 1,51200Cr 12TCr 11TCr 4,82100Cr P/E 2026 *
26.9x
P/E 2027 * 23x
Enterprise Value 4.47TCr 3.27Cr 2.83Cr 2.68Cr 2.43Cr 4.56Cr 313.72Cr 4.58Cr 32Cr 12Cr 159.12Cr 12Cr 12Cr 507.19Cr EV / Sales 2026 *
8.11x
EV / Sales 2027 * 6.92x
Free-Float
60.59%
Yield 2026 *
0.42%
Yield 2027 * 0.47%
Manager TitleAgeSince
Chief Executive Officer 65 20/03/2015
Chief Executive Officer 42 26/03/2021
President 51 13/02/2026
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 01/04/2005
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%+0.82%-1.17%+27.13% 4.59TCr
-0.32%+4.61%+43.90%+26.98% 4.42TCr
-4.36%-5.66%+338.30%+516.88% 4.2TCr
+0.46%-0.83%+6.38%+73.76% 3.96TCr
-0.17%-3.22%+10.29%+38.69% 3.11TCr
-0.65%+5.14%+25.61%+120.17% 1.72TCr
+3.30%-5.03% - - 1.63TCr
+2.17%+7.61%+21.57%+38.71% 1.5TCr
+0.86%+9.05%+0.47%-33.54% 1.34TCr
Average +0.16%+1.18%+55.67%+101.10% 2.94TCr
Weighted average by Cap. -0.35%+0.31%+70.20%+122.64%

Financials

2026 *2027 *
Net sales 5,51800Cr 403.33Cr 349.52Cr 330.36Cr 299.91Cr 562.1Cr 39TCr 565.46Cr 3.94TCr 1.52TCr 20TCr 1.52TCr 1.48TCr 63TCr 6,33700Cr 463.2Cr 401.41Cr 379.4Cr 344.44Cr 645.55Cr 44TCr 649.41Cr 4.53TCr 1.75TCr 23TCr 1.74TCr 1.7TCr 72TCr
Net income 1,53600Cr 112.23Cr 97Cr 92Cr 83Cr 156.41Cr 11TCr 157.35Cr 1.1TCr 424.05Cr 5.46TCr 421.6Cr 412.24Cr 17TCr 1,78500Cr 130.45Cr 113.05Cr 106.85Cr 97Cr 181.8Cr 13TCr 182.89Cr 1.28TCr 492.89Cr 6.35TCr 490.03Cr 479.15Cr 20TCr
Net Debt 2,21500Cr 161.86Cr 140.27Cr 132.58Cr 120.36Cr 225.58Cr 16TCr 226.93Cr 1.58TCr 611.57Cr 7.88TCr 608.02Cr 594.52Cr 25TCr 1,35500Cr 99Cr 86Cr 81Cr 74Cr 138.02Cr 9.5TCr 138.85Cr 968.38Cr 374.19Cr 4.82TCr 372.02Cr 363.76Cr 15TCr
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!